Song Ouyang

Song Ouyang

Auto-generated profile, based on publicly available information

Song Ouyang

Department of Microbial Infection and Immunity, The Ohio State University , Columbus, OH

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
WDWeiwei Duan
Weiwei Duan
YPYuyao Peng
Yuyao Peng
WJWanlin Jin
Wanlin Jin
SOSong Ouyang
Song Ouyang
HYHuan Yang
Huan Yang
Background. Tacrolimus is a second-line immunosuppressant in myasthenia gravis (MG) therapy, which is mainly used in combination with corticosteroids to reduce steroid dose and maintain the effect of immunotherapy. However, few studies have focused on the effect of tacrolimus as single-agent immunotherapy on achieving minimal manifestation status (MMS). Thus, this study is aimed at exploring the efficacy and influencing factors of tacrolimus as single-agent immunotherapy in MG. Methods. Clinical data of 75 nonthymoma MG patients treated with tacrolimus single-agent as initial immunotherapy were retrospectively analyzed. The therapeutic effect was evaluated by Myasthenia Gravis Foundation of America postintervention status. Clinical factors affecting the achievement of MMS and treatment reactivity of different MG subtypes were determined by Cox regression analysis. Results. Tacrolimus was generally safe, with only two patients (2.7%) switching medications due to side effects. 32% of patients had improved symptoms after 1 month of treatment. 69.2% of patients achieved MMS or better after one year. The years old, points, and were indicative of a favorable response, which was independent of gender, course of the disease. As for MG subtypes, ocular and seronegative MG showed better treatment sensitivity. Conclusions. Tacrolimus as single-agent immunotherapy takes effect quickly and can effectively enable nonthymoma MG patients to achieve MMS. Tacrolimus can be used alone for the initial immunotherapy of MG patients, especially for young, mild, and low antibody titer patients.

1 September 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LHLing Huang
Ling Huang
YMYilei Ma
Yilei Ma
HGHui Guo
Hui Guo
NTNa Tang
Na Tang
SOSong Ouyang
Song Ouyang
JZJian Zhang
Jian Zhang
Akt-1 and Akt-2 are the major isoforms of the serine/threonine Akt family that play a key role in controlling immune responses. However, the involvement of Akt-1 and Akt-2 isoforms in antifungal innate immunity is completely unknown. In this study, we show that Akt2−/−, but not Akt1−/−, mice are protected from lethal Candida albicans infection. Loss of Akt-2 facilitates the recruitment of neutrophils and macrophages to the spleen and increases reactive oxygen species expression in these cells. Treating C57BL/6 mice with a specific inhibitor for Akt-2, but not Akt-1, provides protection from lethal C. albicans infection. Our data demonstrate that Akt-2 inhibits antifungal innate immunity by hampering neutrophil and macrophage recruitment to spleens and suppressing oxidative burst, myeloperoxidase activity, and NETosis. We thus describe a novel role for Akt-2 in the regulation of antifungal innate immunity and unveil Akt-2 as a potential target for the treatment of fungal sepsis. Key Points Akt-2 but not Akt-1 inhibits antifungal innate immune responses. Akt-2 suppresses fungal killing in neutrophils and macrophages. Targeting Akt-2 may represent a therapeutic approach for disseminated candidiasis.